ZymoGenetics, Inc. engages in the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases in the areas of hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its preclinical stage internal products include IL-31, for the treatment of atopic dermatitis and inflammatory diseases. The company's phase II internal candidates comprise atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; and IL-21 for the treatment of metastatic melanoma/metastatic renal cell carcinoma. Its phase I out-licensed candidates consist of...
read more
QUOTE
As of 05:47PM EDT May 25, 2012
$
( )
Today's Open:
Today's Close:
| Today's High: |
|
Volume (thous): |
|
| Today's Low: |
|
Avg Vol (thous): |
|
| 52 Week High: |
|
Bid (size): |
|
| 52 Week Low: |
|
Ask (size): |
|
COMPANY INFO
To see the headquarters in Google Street View &trade, drag this yellow guy:
over to the red pointer:
Company Details:
| Symbol: |
ZGEN |
| SIC: |
-
|
| State location: |
WA |
| Sector: |
- |
| State of Inc: |
WA |
| Employees: |
323 |
| Type: |
NASDAQ |
LATEST ARTICLES
In expectation of the second quarter results to be filed next week, ZymoGenetics, Inc. (NASDAQ:ZGEN) stock objected on Friday to the overall declining healthcare industry with a jump up. Though, it is hard to find more than one reason for investors to be optimistic.read more
ZYMOGENETICS, INC (ZGEN) MESSAGE BOARD
